CDN1163 treatment significantly reduces the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuates ER stress response and ER stress-induced apoptosis, and improves mitochondrial biogenesis, possibly through SERCA2-mediated activation of AMP-activated protein kinase pathway.